Keywords: SGLT2; sodium-glucose cotransporter 2; SGLT2i; SGLT2 inhibitor; BDHQ; brief-type self-administered diet history questionnaire; DHQ; self-administered diet history questionnaire; GLP-1; glucagon-like peptide-1; eGFR; estimated glomerular filtration rate; B
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: SGLT2; SGLT1; Gliflozin; Type 1 diabetes; Diabetic kidney disease;
Keywords: Fibroblast growth factor 21; Diabetes; Renal glucose reabsorption; SGLT2; PPAR δ;
Keywords: diabetes; heart failure; echocardiography; screening; DCM; diabetic cardiomyopathy; DD; diastolic dysfunction; DM; diabetes mellitus; GLS; global longitudinal strain; HFpEF; heart failure with preserved ejection fraction; O-GlcNAc; β-N-acetylglucosamine;
Keywords: 3Ã-HSD; 3Ã-hydroxysteroid dehydrogenase-isomerase; ABPM; ambulatory blood pressure monitoring; Ang II; angiotensin II; ARB; angiotensin receptor blocker; AT1; angiotensin receptor type 1; AT2; angiotensin receptor type 2; ACE; angiotensin-converting enz
Keywords: Diabetes type 2; SGLT2 inhibitors; Cardiovascular disease; Kidney disease; Safety; Amputation; Fracture; Systematic review; Randomised controlled trials; AKI; Acute kidney impairment; CVD; Cardiovascular disease; MACE; Major macrovascular event; SGLT2; So
Keywords: AKI; acute kidney injury; α-SMA; αâsmooth muscle actin; CKD; chronic kidney disease; ECM; extracellular matrix; CTGF; (connective tissue growth factor); DC; dendritic cells; DTR; diphtheria toxin receptor; EGF; epidermal growth factor; EMT; epithelial
Keywords: ADA; American Diabetes Association; BMI; body mass index; CGM; continuous glucose monitoring; DPP-4; dipeptidyl peptidase 4; GLP-1; glucagon-like peptide 1; mTORC1/2; mammalian target of rapamycin complex 1/2; OGTT; oral glucose tolerance test; PTDM; post
Keywords: Empagliflozin; Heart failure; SGLT2 inhibitor; Type 2 diabetes mellitus; CKD; chronic kidney disease; HF; heart failure; SGLT2; sodium glucose co-transporter 2; T2DM; type 2 diabetes mellitus;
Keywords: C-IMT; carotid intima-media thickness test; CV; cardiovascular; DPP4; dipeptidyl peptidase-4; DPP4i; DPP4 inhibitors; GLP1; glucagon-like peptide 1; HbA1c; glycated haemoglobin; HF; heart failure; HR; hazard ratio; MACE; major adverse cardiac event; MI;
Keywords: Glucose homeostasis; Glucose metabolism; Glucose physiology; Renal glucose metabolism; Glucose transporters; Sodium-glucose co-transporter 2; SGLT2; Diabetes mellitus; FFA; free fatty acids; GLUT; glucose transporter; SGLT; sodium-glucose co-transporter;
Keywords: SGLT1; SGLT2; Phlorizin; Hippocampus; Neurodegeneration; Fluoro-Jade C; Pilocarpine; Status epilepticus;
Keywords: GLUT; Glucose transporter; T1DM; Type-1 diabetes mellitus; T2DM; Type-2 diabetes mellitus; PKB/Akt; protein kinase B; GSK-3; glycogen synthase kinase-3; PGC-1α; peroxisome proliferator-activated receptor gamma coactivator-1α; FOXO; forkhead box O; VLDL;
Keywords: type 2 diabetes; weight loss; obesity; impaired glucose tolerance; impaired fasting glucose; diabetes prevention; HOMA-IR; Homeostasis Model assessment-Insulin Resistance; HOMA-β%; Homeostasis Model Assessment-β-cell function; SGLT2; Sodium-glucose co-t
Keywords: Nonalcoholic fatty liver disease (NAFLD); Nonalcoholic steatohepatitis (NASH); Thiazolinediones; Pioglitazone; Dipeptidyl peptidase 4 (DPP-4) inhibitors; Glucagon-like peptide-1 receptor agonists (GLP-1RA); BCAAs; branched-chain amino acids; ARB; angioten
Keywords: Tissue targeting; Transporter; Kidney; Liver; SGLT2; OATP;
Keywords: Sodium glucose cotransporter 2; SGLT2; SGLT2 inhibitors; Type 2 diabetes; Antihyperglycemic agents;
Keywords: AGE; advanced glycation end-products; AGE-BSA; glycated bovine serum albumin; BSA; bovine serum albumin; DHR; Dihydrorhodamine; DIOC6; 3,3â²-dihexyloxacarbocyanine iodide; DMEM; Dulbecco's minimum essential medium; DN; diabetic nephropathy; GLUT; gluco
Keywords: AE; adverse event; AUC; area under the concentration-time curve; BMI; body mass index; C150; canagliflozin 150Â mg; C300; canagliflozin 300Â mg; CI; confidence interval; CRC; clinical research center; CV; coefficient of variation; FPG; fasting plasma gluc
Keywords: Type 2 diabetes; Infections; Genital; Urinary; Glucosuria; SGLT2;
Keywords: AGE; advanced glycation end product; aBMD; areal bone mineral density; BMD; bone mineral density; BMI; body mass index; DPP-4; dipeptidyl peptidase-4; DXA; dual-energy X-ray absorptiometry; eBMD; estimated bone mineral density; GLP-1; glucagon-like peptid
Keywords: ACE-I; angiotensin-converting enzyme inhibitor; ARB; angiotension receptor blocker; BMI; body mass index; Cr; creatinine; CVD; cardiovascular disease; DPP-4; dipeptidyl peptidase 4; GAD-65; glutamic acid decarboxylase; GLP-1; glucagon-like peptide 1; GFR;
Keywords: AQP5; Water channel; Hyperglycemia; Lens cataract; Lens transparency; GLUT1; GLUT3; Sodium-dependent glucose cotransporters; SGLT1; SGLT2;
Keywords: Dapagliflozin; Glucosuria; Sodium glucose cotransporter 2; SGLT2; Urinary tract infection; UTI;
Design, synthesis and biological evaluation of nitric oxide releasing derivatives of dapagliflozin as potential anti-diabetic and anti-thrombotic agents
Keywords: Cardiovascular complications; Diabetes; SGLT2; Hybrid; NO donor;
Worsening Heart Failure During the Use of DPP-4 Inhibitors
Keywords: diabetes; DPP-4 inhibitors; heart failure risk; saxagliptin; sitagliptin; AMP; adenosine monophosphate; DPP; dipeptidyl peptidase; GLP; glucagon-like peptide; SDF; stromal cell-derived factor; SGLT2; sodium-glucose transporter 2;
Renal protective effect of SGLT2 inhibitor dapagliflozin alone and in combination with irbesartan in a rat model of diabetic nephropathy
Keywords: ABP; arterial blood pressure; ACE; angiotensin converting enzyme; AGEs; advanced glycation end products; ARB; angiotensin receptor blocker; BUN; blood urea nitrogen; Cr Cl; creatinine clearance; DN; diabetic nephropathy; GSH-Px; glutathione peroxidase; Hb
Antidiabetic effects of SGLT2 inhibitor ipragliflozin in type 2 diabetic mice fed diets containing different carbohydrate contents
Keywords: Ipragliflozin; SGLT2; Hyperglycemia; Obese; Diabetes;
SGLT1 inhibition: Pros and cons
Keywords: SGLT1; SGLT2; Sotagliflozin; Canagliflozin; Glycosuria;
Antidiabetic and antiobesity effects of SGLT2 inhibitor ipragliflozin in type 2 diabetic mice fed sugar solution
Keywords: Ipragliflozin; SGLT2; Hyperglycemia; Urinary glucose excretion; Obesity; Diabetes;
Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes
Keywords: ANCOVA; analysis of covariance; CANA; canagliflozin; CANVAS; CANagliflozin cardioVascular Assessment Study; CI; confidence interval; CRP; C-reactive protein; GLIM; glimepiride; HDL-C; high-density lipoprotein cholesterol; IL-6; interleukin-6; LDL-C; low-d
Identification of an oxime-containing C-glucosylarene as a potential inhibitor of sodium-dependent glucose co-transporter 2
Keywords: Oxime; Sodium-dependent glucose co-transporter; Aryl C-glycosides; Diabetes management; Ac2O; acetic anhydride; AMG; α-methyl-d-glucopyranoside; BF3·OEt2; boron trifluoride etherate; CHO; Chinese hamster ovary; DMAP; 4-N,N-dimethylaminopyridine; hERG; h
PI3K pathway in prostate cancer: All resistant roads lead to PI3K
Keywords: CRPC; castration-resistant prostate cancer; ADT; androgen deprivation therapy; PI3K; phosphoinositide 3-kinase; AR; androgen receptor; PTEN; phosphatase and tensin homologue deleted on chromosome 10; INPP4B; inositol polyphosphate 4-phosphatase type II; P
Euglycemic Diabetic Ketoacidosis with Elevated Acetone in a Patient Taking a Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor
Keywords: sodium-glucose cotransporter-2 inhibitors; SGLT2; euglycemic diabetic ketoacidosis; acetone; canagliflozin;
Sodium-dependent glucose transporters (SGLT) in human ischemic heart: A new potential pharmacological target
Keywords: Ischemic heart disease; Myocardial disease; Cardiac hypertrophy; Heart failure; Empagliflozin; SGLT1; SGLT2;
Effect of sodium-glucose cotransporter 2 (SGLT2) inhibition on weight loss is partly mediated by liver-brain-adipose neurocircuitry
Keywords: Diabetes; Obesity; SGLT2 inhibitor; Glycogen depletion signal; Liver-brain-adipose neurocircuitry; HVx; hepatic vagotomy; SGLT2; sodium-glucose cotransporter 2; TOFO; tofogliflozin; PKA; protein kinase A;
Empagliflozin Prevents Worsening of Cardiac Function in an Experimental Model of Pressure Overload-Induced Heart Failure
Keywords: empagliflozin; heart failure; SGLT2; sodium/glucose cotransporter 2 inhibitor; HF; heart failure; LV; left ventricular; SGLT2; sodium/glucose cotransporter 2; TAC; transverse aortic constriction;
Effects of phosphate binders on the gastrointestinal absorption of arsenate and of an SGLT2 inhibitor drug on the urinary excretion of arsenite in mice
Keywords: Arsenic; Aluminium hydroxide; Lanthanum carbonate; Sevelamer; Dapagliflozin; SGLT2;
The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats
Keywords: ACh; acetylcholine; AGE; advanced glycation end products; ALDH-2; mitochondrial aldehyde dehydrogenase; CCL-2; see MCP-1; ChIP; chromatin immunoprecipitation; COX2; cyclooxygenase-2; CRP; C-reactive protein; DHE; dihydroethidine; DHFR; dihydrofolate reduc
Synthesis and biological evaluation of novel dioxa-bicycle C-aryl glucosides as SGLT2 inhibitors
Keywords: SGLT2; C-aryl glucosides; Diabetes;
The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration
Keywords: AMP-activated protein kinase AMPK; Lipogenesis; SGLT2; Prostate cancer; Lung cancer; Breast cancer; Colon cancer; mTOR; Cancer metabolism; Glucose uptake; 2-DG; 2-deoxy-d-glucose; ACC; acetyl-CoA carboxylase; AD-AMPKDN; adenoviral alpha-1 dominant negativ
The effect of dipeptidyl peptidase-IV inhibition on circulating T cell subpopulations in patients with type 2 diabetes mellitus
Keywords: μM; μmol/l; BMI; body mass index; CD; cluster of differentiation; DM2; diabetes mellitus type 2; DPP-IV; dipeptidyl peptidase-IV; GIP; gastric inhibitory polypeptide; GLP-1; glucagon like peptide-1; HbA1c; glycated hemoglobin; IFNgamma; interferon gamma
Beta-2-microglobulin (B2M) expression in the urinary sediment correlates with clinical markers of kidney disease in patients with type 1 diabetes
Keywords: Diabetic kidney disease; Diabetic nephropathy; Urinary sediment; Beta-2-microglobulin; Focal segmental glomerulosclerosis; ACEI; (angiotensin converting enzyme inhibitors); ACR; (albumin-to-creatinine ratio); AGE; (advanced glycation end products); ARB; (
Modifications d'activité des transporteurs rénaux du glucose : données moléculaires et pharmacologiques
Keywords: SGLT2; Transport rénal du glucose; Glucose et rein; Mutation des SGLT2; Glycosurie; Diabète rénal; Diabète; Renal glucose transport; Glucose and kidney; SGLT2; SGLT2 mutation; Renal diabetes; Diabetes; Glycosuria;
A quantitative LC-MS/MS method for determining ipragliflozin, a sodium-glucose co-transporter 2 (SGLT-2) inhibitor, and its application to a pharmacokinetic study in rats
Keywords: SGLT2; Ipragliflozin; Empagliflozin; Liquid chromatography-tandem mass spectrometry;
Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus
Keywords: empagliflozin; glycemic control; metformin; pioglitazone; SGLT2; type 2 diabetes mellitus;
LX4211 Therapy Reduces Postprandial Glucose Levels in Patients With Type 2 Diabetes Mellitus and Renal Impairment Despite Low Urinary Glucose Excretion
Keywords: fasting plasma glucose; LX4211; pharmacokinetics; postprandial glucose; renal impairment; SGLT1; SGLT2; urinary glucose excretion;
Novel frame-shift mutation in Slc5a2 encoding SGLT2 in a strain of senescence-accelerated mouse SAMP10
Keywords: Sodium-glucose co-transporter; SGLT2; Senescence-accelerated mouse; SAMP10; Frame-shift mutation; Glucosuria;
Pharmacokinetic and pharmacodynamic study of ipragliflozin in Japanese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled study
Keywords: Ipragliflozin; Fasting glucose; Postprandial glucose; SGLT2; Type 2 diabetes
Blood pressure effects of sodium–glucose co-transport 2 (SGLT2) inhibitors
Keywords: Diabetes; hypertension; glucose; transporters; SGLT2